Building Diverse Teams: Sustainability in Elaia's Portfolio
As part of the 2024 Elaia Sustainability Report, we’re featuring startups from the portfolio that stand out for their commitment to ESG. Next up, those scaling with diversity in mind.
Dive into the full 2024 Sustainability Report at elaia.com/esg.
In the same way that we look to build diversity internally at Elaia, we also believe diverse teams drive performance in the companies we invest in. We believe in the power of having a range of perspectives and experiences in bringing the best ideas to the table and being able to execute them. We invest in companies that center this in their recruitment process, even at an early stage.
Portfolio Case Study: Mirakl
Mirakl, founded in 2012, provides SaaS solutions that enable retailers and B2B players to digitize and expand product assortment through marketplace and dropship, improve efficiency in supplier catalog management and payments and boost profits through retail media. Diversity and inclusion are embedded in Mirakl’s culture: 67% of its Executive Committee members are women and Mirakl has formalised a comprehensive framework for supporting parenthood to prevent women from dropping out of their careers.
The company also invests in unconscious bias training and partners with organisations such as Technovation Girls France. Today, 34% of Mirakl’s workforce is female (compared to the 28% European tech industry average) and employees represent 40 nationalities. With 98% of staff saying Mirakl provides an inclusive workplace and a Gender Equality Index score of 93/100 in France, diversity remains a core driver of the company’s growth and success.
Portfolio Case Study: Inato
Inato is a tech-for-good company striving to bring clinical research to each and every patient. To do this, they are building the world’s first clinical trial marketplace to create greater visibility, access, and engagement across a more diverse population of doctors and their patients.
At Inato, employees have the opportunity to make a daily positive impact. Drug development is a complex and rewarding endeavour: their platform enables sponsors and community- based researchers to work together when developing effective treatments for diseases affecting millions of people. They are on a mission to put more diversity into clinical trials, and that starts in-house, with building a team representative of the greater population.